A research-intensive drugmaker with cash-funded investment capacity
The multi-year record combines sustained revenue growth and rising operating profit with substantial recurring research and development spending. Cash generation can be uneven as investment and working capital fluctuate, while a sizable cash position and no reported debt provide capacity to fund product-supply and pipeline investment alongside dividends.